These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 3366230)

  • 1. High-dose desferrioxamine as a cause of growth failure in thalassemic patients.
    Piga A; Luzzatto L; Capalbo P; Gambotto S; Tricta F; Gabutti V
    Eur J Haematol; 1988 Apr; 40(4):380-1. PubMed ID: 3366230
    [No Abstract]   [Full Text] [Related]  

  • 2. [Audiologic evaluation of patients with thalassemic syndromes treated with desferrioxamine B].
    Gaini RM; Moretti E; Boffa C; Terzoli S; Carnelli V
    Pediatr Med Chir; 1988; 10(5):503-4. PubMed ID: 3241755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.
    Graziano JH; Markenson A; Miller DR; Chang H; Bestak M; Meyers P; Pisciotto P; Rifkind A
    J Pediatr; 1978 Apr; 92(4):648-52. PubMed ID: 633032
    [No Abstract]   [Full Text] [Related]  

  • 4. Normal serum ferritin levels following prolonged desferrioxamine therapy: Melbourne experience.
    Matthews RN
    Birth Defects Orig Artic Ser; 1988; 23(5B):117-22. PubMed ID: 3390533
    [No Abstract]   [Full Text] [Related]  

  • 5. Growth plate injury of the long bones in treated beta-thalassemia.
    Orzincolo C; Scutellari PN; Castaldi G
    Skeletal Radiol; 1992; 21(1):39-44. PubMed ID: 1546335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth failure and bone lesions due to desferrioxamine in thalassaemic patients.
    Caruso-Nicoletti M; Di Bella D; Pizzarelli G; Leonardi C; Sciuto C; Coco M; Di Gregorio F
    J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():957-60. PubMed ID: 10091171
    [No Abstract]   [Full Text] [Related]  

  • 7. [Echocardiographic measurements in transfused thalassemic major children].
    Balducci G; Antonelli GF; Mautone A; Di Lecce A; Schettini F
    Minerva Pediatr; 1980 May; 32(9):583-7. PubMed ID: 7464753
    [No Abstract]   [Full Text] [Related]  

  • 8. Physical growth patterns and dental caries in thalassemia.
    Gomber S; Dewan P
    Indian Pediatr; 2006 Dec; 43(12):1064-9. PubMed ID: 17202603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
    Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
    [No Abstract]   [Full Text] [Related]  

  • 10. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage.
    Porter JB; Jaswon MS; Huehns ER; East CA; Hazell JW
    Br J Haematol; 1989 Nov; 73(3):403-9. PubMed ID: 2605127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia.
    Cossu P; Toccafondi C; Vardeu F; Sanna G; Frau F; Lobrano R; Cornacchia G; Nucaro A; Bertolino F; Loi A; De Virgiliis S; Cao A
    Eur J Pediatr; 1981 Nov; 137(3):267-71. PubMed ID: 7318837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Thalassemic cardiopathy: serial echocardiographic evaluation].
    Bosi S; Spinolo L; Cavallini B; Guadagni C; Lama A; Santarelli R; Baccini C
    G Clin Med; 1982 Apr; 63(4):248-54. PubMed ID: 7128980
    [No Abstract]   [Full Text] [Related]  

  • 13. Allergy to desferrioxamine.
    Romeo MA; Di Gregorio F; Schiliro G
    J Inherit Metab Dis; 1984; 7(3):121. PubMed ID: 6438394
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment with deferiprone (L1) in a thalassemic patient with bone lesions due to desferrioxamine.
    Mangiagli A; De Sanctis V; Campisi S; Di Silvestro G; Urso L
    J Pediatr Endocrinol Metab; 2000 Jun; 13(6):677-80. PubMed ID: 10905396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years.
    Jetsrisuparb A; Komvilaisak P; Wiangnon S; Jetsrisuparb C
    J Pediatr Hematol Oncol; 2010 Jul; 32(5):400-3. PubMed ID: 20505533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lens opacities in thalassemia.
    Bloomfield SE; Markenson AL; Miller DR; Peterson CM
    J Pediatr Ophthalmol Strabismus; 1978; 15(3):154-6. PubMed ID: 739345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral ascorbic acid and iron excretion in thalassemic children treated with desferrioxamine-methansulfonate (Desferal).
    Hathirat P; Isarangkura P; Areekul S; Pleehachinda R; Tuntawiroon M
    Birth Defects Orig Artic Ser; 1988; 23(5B):129-33. PubMed ID: 3390535
    [No Abstract]   [Full Text] [Related]  

  • 18. Current treatment of Cooley's anemia. Intravenous chelation therapy.
    Cohen AR; Martin M; Schwartz E
    Ann N Y Acad Sci; 1990; 612():286-92. PubMed ID: 2291556
    [No Abstract]   [Full Text] [Related]  

  • 19. Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA.
    Wonke B; Hoffbrand AV; Aldouri M; Wickens D; Flynn D; Stearns M; Warner P
    Arch Dis Child; 1989 Jan; 64(1):77-82. PubMed ID: 2923478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron chelation in transfusion-dependent thalassemia with chronic hepatitis.
    De Virgiliis S; Cossu P; Sanna G; Frau F; Loi E; Lobrano R; Nucaro A; Toccafondi C; Cornacchia G; Loi A; Cao A
    Acta Haematol; 1982; 67(1):49-56. PubMed ID: 6800202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.